Similar articles

• Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure.

  Lewis DA, Gurram NR, Abraham WT, Akers WS. Lewis DA, et al. Am J Health Syst Pharm. 2003 Aug 15;60 Suppl 4:S16-20. doi: 10.1093/ajhp/60.suppl_4.S16. Am J Health Syst Pharm. 2003. PMID: 12966902
• Intravenous nesiritide in acute heart failure.

  Knox MA, Dancy T, Mook W, Pschirer JJ. Knox MA, et al. Am J Ther. 2005 May-Jun;12(3):233-7. Am J Ther. 2005. PMID: 15891267
• Nesiritide utilization evaluation in a university teaching hospital.

  Cheng JW, Merl MY, Nguyen HM, Caliendo GC, Meyers J. Cheng JW, et al. J Clin Pharm Ther. 2005 Oct;30(5):447-53. doi: 10.1111/j.1365-2710.2005.00665.x. J Clin Pharm Ther. 2005. PMID: 16164491
• Nesiritide in acute decompensated heart failure: current status and future perspectives.

  Mohammed SF, Korinek J, Chen HH, Burnett JC, Redfield MM. Mohammed SF, et al. Rev Cardiovasc Med. 2008 Summer;9(3):151-8. Rev Cardiovasc Med. 2008. PMID: 18953274 Free PMC article. Review.
• Critical review and recommendations for nesiritide use in the emergency department.

  Collins SP, Hinckley WR, Storrow AB. Collins SP, et al. J Emerg Med. 2005 Oct;29(3):317-29. doi: 10.1016/j.jemermed.2005.01.028. J Emerg Med. 2005. PMID: 16183453 Review.